Another study with vaccinia virus (VV) and CTLA4 inhibition in a syngeneic subcutaneous mouse renal adenocarcinoma model showed that if the combination of virus with anti-CTLA4 was administered on the same day (Day 0) the therapeutic effect of the addition of anti-CTLA4 was diminished. The gene discussed is CTLA4; the disease is papillary renal cell carcinoma.